Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German software firm SAP ...

Novo Nordisk and Deep Apple Therapeutics Inc. have entered a research collaboration and exclusive license agreement.

Denmark-headquartered Novo Nordisk (NVO) has entered into a collaboration and exclusive worldwide license agreement with ...

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and antibodies.

If E.U. and U.S. negotiators make use of the delay to negotiate a deal that will lower or remove tariffs entirely, that would be even better news for Novo Nordisk stock -- and it's probably what ...

But the company's pharmacy benefits unit Evernorth has reached a deal with drug makers Ely Lilly and Novo Nordisk which it said will bring prices down for employers and their workers. "This ...

The new deal ... Novo's Wegovy its primary weight loss drug starting in the second half of the year, which would mean coverage for Lilly's Zepbound would no longer be preferred. Novo Nordisk ...